Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 31.9% in January

Immix Biopharma, Inc. (NASDAQ:IMMX) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 2,990,326 shares, a growth of 31.9% from the January 15th total of 2,266,456 shares. Approximately 12.7% of the company’s shares are sold short. Based on an average daily trading volume, of 961,464 shares, the short-interest ratio is presently 3.1 days. Based on an average daily trading volume, of 961,464 shares, the short-interest ratio is presently 3.1 days. Approximately 12.7% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on IMMX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Mizuho started coverage on Immix Biopharma in a research report on Monday, February 9th. They issued an “outperform” rating and a $14.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $11.00.

Hedge Funds Weigh In On Immix Biopharma

Large investors have recently modified their holdings of the stock. Marshall Wace LLP boosted its stake in Immix Biopharma by 3,495.4% in the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after purchasing an additional 1,923,708 shares in the last quarter. Bleichroeder LP lifted its stake in shares of Immix Biopharma by 17.6% in the fourth quarter. Bleichroeder LP now owns 1,000,000 shares of the company’s stock worth $5,230,000 after buying an additional 150,000 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in shares of Immix Biopharma during the fourth quarter valued at approximately $176,000. Jane Street Group LLC lifted its position in Immix Biopharma by 1,016.4% in the 4th quarter. Jane Street Group LLC now owns 167,132 shares of the company’s stock valued at $874,000 after acquiring an additional 152,162 shares in the last quarter. Finally, Tocqueville Asset Management L.P. boosted its holdings in shares of Immix Biopharma by 70.3% during the 4th quarter. Tocqueville Asset Management L.P. now owns 68,550 shares of the company’s stock valued at $359,000 after acquiring an additional 28,300 shares during the last quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Down 1.3%

IMMX opened at $7.33 on Monday. Immix Biopharma has a 52 week low of $1.34 and a 52 week high of $7.73. The stock has a market cap of $388.20 million, a PE ratio of -9.52 and a beta of 0.31. The business has a 50 day moving average of $5.74 and a 200-day moving average of $3.88.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.